Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:
Annex XII – Amendment to the Information on the Period of Validity of a Resolution on the Benefit Assessment of Medicinal Products with New Active Ingredients Pursuant to Section 35a SGB V
Atezolizumab (Reassessment due to New Scientific Knowledge: Urothelial carcinoma)

of 6 April 2023

At its session on 6 April 2023, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. In Annex XII, the provision in Section II on the period of validity of the resolution on the benefit assessment of Atezolizumab of 20 June 2019, as last amended by the resolution of 16 June 2022, shall be amended as follows:

1. The information "1." shall be deleted.

2. The sentence "2. The period of validity is limited until 1 May 2023." shall be deleted.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 6 April 2023.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 6 April 2023

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken